Covered recipient · General Payments record
MARK T INDA
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2021–2024
$4,122.27
- Reported across 288 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $804.18 | 48 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $337.10 | 24 |
| Astellas Pharma US Inc | $153.52 | 7 |
| GlaxoSmithKline, LLC. | $135.00 | 7 |
| Lilly USA, LLC | $87.54 | 5 |
| PFIZER INC. | $52.86 | 3 |
| Exact Sciences Corporation | $23.09 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $15.07 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (48)
Sorted by paying entity, then date · as published by CMS
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.